BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

...of farletuzumab on ClinicalTrials.gov.TARGETSFOLR1 (FR-alpha; FOLR) – Folate receptor 1 Danielle Golovin farletuzumab (MORAb-003) MOv18 IgE mirvetuximab soravtansine (IMGN853) MORAb-202 STRO-002 TPIV200 (TPIV 200, TPIV200/huFR-1) Folate...
BioCentury | Jun 15, 2018
Financial News

After announced merger, TapImmune raises $70M

...platform with TapImmune's peptide vaccine portfolio. The most advanced product in the combined pipeline, TapImmune's TPIV200...
...Cell Therapy. Piper Jaffray and Nomura were placement agents. TapImmune (NASDAQ:TPIV), Jacksonville, Fla. Allison Johnson TPIV200/huFR-1 (TPIV 200, TPIV200) Marker...
BioCentury | Jun 8, 2018
Financial News

TapImmune shares climb on $70M offering

...platform with TapImmune's peptide vaccine portfolio. The most advanced product in the combined pipeline, TapImmune's TPIV200...
...and International Society for Cell Therapy. Piper Jaffray and Nomura were placement agents. Allison Johnson TPIV200/huFR-1 (TPIV 200, TPIV200) Marker...
BioCentury | Jun 1, 2018
Company News

TapImmune, Marker Therapeutics merge

...therapy platform with TapImmune's peptide vaccine portfolio. The most advanced product in the combined pipeline, TPIV200...
...TapImmune Inc. (OTCQB:TPIV), Jacksonville, Fla. Marker Therapeutics Inc., New Brighton, Minn. Business: Cancer Shannon Lehnbeuter TPIV200/huFR-1 (TPIV 200, TPIV200) Baylor TapImmune...
BioCentury | Feb 16, 2017
Clinical News

TPIV 200: Ph II ongoing

...recommended continuation of an open-label, U.S. Phase II trial of 165 and 500 μg intradermal TPIV 200...
...IIb or III TNBC of the planned 80. TapImmune Inc. (NASDAQ:TPIV), Jacksonville, Fla. Product: TPIV200/huFR-1 (TPIV 200...
...survival and safety Status: Phase II ongoing Milestone: Complete Phase II enrollment (year end 2017) Julian Zhu TPIV 200 TPIV200/huFR-1 TapImmune...
BioCentury | Feb 8, 2017
Clinical News

TPIV 200: Ph II started

...TapImmune began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 500 µg intradermal TPIV 200 as...
...patients who have previously received ≥2 platinum-containing regimens. TapImmune Inc. (NASDAQ:TPIV), Jacksonville, Fla. Product: TPIV200/huFR-1 (TPIV 200...
...response rate by immune-related RECIST criteria and CA-125 response Status: Phase II started Milestone: NA Chris Lieu TPIV 200 TPIV200/huFR-1 TapImmune...
BioCentury | Jul 11, 2016
Clinical News

TPIV200/huFR-1: Phase II started

...plc (LSE:AZN; NYSE:AZN, London, U.K.) began an open-label, U.S. Phase II trial to evaluate intradermal TPIV200...
...treat lung, bladder and head and neck cancers. TapImmune Inc. (OTCQB:TPIV), Jacksonville, Fla. Product: TPIV200/huFR-1 (TPIV 200...
BioCentury | Jul 11, 2016
Clinical News

Durvalumab: Phase II started

...OTCQB:TPIV, Jacksonville, Fla.) and AstraZeneca began an open-label, U.S. Phase II trial to evaluate intradermal TPIV200...
...IV durvalumab on days 1 and 15 for 12 cycles in about 40 patients. TapImmune’s TPIV200...
BioCentury | Jun 27, 2016
Clinical News

TPIV200/huFR-1: Phase II started

...TapImmune began an open-label, U.S. Phase II trial to evaluate 2 dose levels of intradermal TPIV 200...
...6 months followed by boosters every 6 months. TapImmune Inc. (OTCQB:TPIV), Jacksonville, Fla. Product: TPIV200/huFR-1 (TPIV 200...
BioCentury | Oct 5, 2015
Company News

TapImmune, U.S. Department of Defense, Mayo Clinic cancer news

...DoD awarded Mayo a $13.3 million grant to conduct a Phase II trial of TPIV200 to...
...under a 2014 deal with Mayo and received exclusive, worldwide rights to develop and commercialize TPIV200...
Items per page:
1 - 10 of 10